Wednesday, January 24, 2018 9:01:26 PM
Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania
NEW HAVEN, Conn., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics firm Precipio, Inc. (NASDAQ:PRPO), today announced it is collaborating with the cytogenetics laboratory at the University of Pennsylvania to conduct an external validation and evaluation of IV-Cell, Precipio’s cytogenetics media.
The market for cytogenetics media is estimated to exceed $100M annually; most of the cytogenetics reagents have seen little development in the past 25 years, presenting an opportunity for a breakthrough media such as IV-Cell.
Validation by an external laboratory represents the first step in bringing this product to market. The completion of this study is expected to provide strong, independent evidence of its performance, and will serve as an important tool during discussions with the leading manufacturers to acquire this technology.
Study Goals
The study will be conducted over a period of approximately six to eight weeks and will include the testing of over 50 clinical specimens. During the study, the Penn team will do a side-by-side comparison between their current culture media, and Precipio’s media.
The study will evaluate two key elements of Precipio’s media. First, its ability to enable laboratory technicians to culture multiple cell lineages simultaneously compared to their existing media that requires the laboratory to select up-front the target cell lineage; once that cell lineage is selected, it cannot be changed. The ability to culture multiple cell lineages using IV-Cell represents a significant advantage that can provide the laboratory with a more complete picture of the patient specimen, and can ultimately lead to a more accurate diagnosis.
The second advantage, is a significantly higher resolution of the chromosomal bands that are created during the process. This increases the cytogeneticists’ ability to correctly identify any abnormalities that may be present, resulting in a more accurate diagnosis.
"If the trial in our laboratory successfully demonstrates that Precipio’s IV-Cell media works, it could be very useful in the field of cytogenetics,” said Jennifer Morrissette, PhD, Associate Professor of Clinical Pathology and Clinical Director of the Center for Personalized Diagnostics in the Perelman School of Medicine at the University of Pennsylvania.
Precipio developed the cytogenetics media earlier in 2017 and has been using it clinically in its laboratory for the past six months. IV-Cell has been successfully applied on more than 100 clinical patient cases. In parallel with this validation study, Precipio continues to dialogue with industry manufacturers to discuss a potential license or acquisition of the IP generated from this invention.
"We are delighted to have partnered with a prominent laboratory such as the one at the University of Pennsylvania to conduct this trial. Their immediate interest in setting up a trial, as well as their enthusiasm in a joint publication and presentation in the upcoming American Cytogenetics Conference, the industry’s leading conference, is a testament to the exciting breakthrough potential of our product,” said Ilan Danieli, President and Chief Executive Officer of Precipio. "We look forward to a close collaboration with Penn, and are eager to see the results of their experience using the media, and its potential impact on clinical care. Ultimately this goes directly to our vision of reducing diagnostic errors and saving lives through multiple avenues, combining academic expertise and innovation to deliver a more accurate diagnosis," Mr. Danieli concluded.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Recent PRPO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:12:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:11:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:10:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:09:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:09:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:06:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:06:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:00:48 PM
- Precipio Announces Employee Stock Option Plan Repricing • GlobeNewswire Inc. • 09/06/2024 08:00:00 PM
- Precipio Announces Q2-2024 Shareholder Update Call • GlobeNewswire Inc. • 08/15/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:39:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:05:33 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/02/2024 06:15:53 PM
- Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024 • GlobeNewswire Inc. • 07/17/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:30:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/13/2024 08:59:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/13/2024 08:58:03 PM
- Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders • GlobeNewswire Inc. • 06/13/2024 08:00:00 PM
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting • GlobeNewswire Inc. • 06/12/2024 08:00:00 PM
- Precipio Provides Status Update on Current Business Matters • GlobeNewswire Inc. • 06/12/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:01:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:20:29 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM